CHAPTER 3.1 94 pronounced, with 12% fewer CV deaths in females, as opposed to a 31% increased number of observed CV deaths in male trial participants than expected (SMR 0.88; 95% 0.75 to 1.02 vs SMR 1.31; 95% CI 1.22 to 1.40, for females and males respectively). After full adjustment for all HF prognostic factors in model 4, these observed sex differences remained in place with 11% fewer CV deaths in females participating in trials than expected, compared to 43% more observed CV deaths in male trial participants than expected (SMR 0.89; 95CI 0.76 to 1.03 versus SMR 1.43; 95% CI 1.33 to 1.53) (Figure 3). The sensitivity analyses of SMRs calculated in subgroups of those only in sinus rhythm or those only with CAD did not meaningfully differ from the total population (Supplementary Figure 2 and Supplementary Figure 3).
RkJQdWJsaXNoZXIy MjY0ODMw